Sustainable farming of C. asiatica for madecassic acid and other triterpenoids:
- T. T. P. Tran, N. T. Pham, N. X. Nguyen, C. V. Tran, L. V. Tran, L. T. Nguyen, D. T. Nguyen, N. T. N. Huynh, T. L. Nguyen, Y. T. H. Be, M. D. Garrett, C. J. Serpell, S. V. Tran, Comparison of organic and conventional production methods in accumulation of biomass and bioactive compounds in Centella asiatica (L.) urban, ChemRxiv, 2023, DOI: 10.26434/chemrxiv-2023-q9vvc
Anticancer properties of Centella asiatica extracts:
- L. Tran Van, Q. N. Vo Thi, C. Tran Van, P. T. Tran Thi, N. Pham Thi, T. Nguyen Tuan, T. H. Le Thi, N. Nguyen Thi, T. Do Thi and S. Tran Van, Synthesis of asiatic acid derivatives and their cytotoxic activity, Med. Chem. Res., 2018, 27, 1609–1623.
- T. Van Loc, V. T. Q. Nhu, T. Van Chien, L. T. T. Ha, T. T. P. Thao, T. Van Sung, Synthesis of madecassic acid derivatives and their cytotoxic activity, Zeitschrift für Naturforsch. B, 2018, 73, 91–98.
- P. T. Ninh, V. T. Q. Nhu, T. T. P. Thao, L. T. T. Ha, T. Van Loc, T. Van Chien and T. Van Sung, Chemical composition and the inhibition of acetyl cholinesterase activity of Centella asiatica from Quang Tho village, Quang Dien district, Thua Thien – Hue province, Vietnam J. Chem., 2019, 57, 347–351.
Cancer therapeutics:
- W. Fry, D. C. Bedford, P. H. Harvey, A. Fritsch, P. R. Keller, Z. Wu, E. Dobrusin, W. R. Leopold, A. Fattaey, M. D. Garrett, Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6., J. Biol. Chem., 2001, 276, 16617–23.
- U. Banerji, E. J. Dean, J. A. Pérez-Fidalgo, G. Batist, P. L. Bedard, B. You, S. N. Westin, P. Kabos, M. D. Garrett, M. Tall, H. Ambrose, J. C. Barrett, T. H. Carr, S. Y. A. Cheung, C. Corcoran, M. Cullberg, B. R. Davies, E. C. de Bruin, P. Elvin, A. Foxley, P. Lawrence, J. P. O. Lindemann, R. Maudsley, M. Pass, V. Rowlands, P. Rugman, G. Schiavon, J. Yates and J. H. M. Schellens, A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA -Mutated Breast and Gynecologic Cancers, Clin. Cancer Res., 2018, 24, 2050–2059.
- M. I. Walton, P. D. Eve, A. Hayes, A. T. Henley, M. R. Valenti, A. K. D. H. Brandon, G. Box, K. J. Boxall, M. Tall, K. Swales, T. P. Matthews, T. McHardy, M. Lainchbury, J. Osborne, J. E. Hunter, N. D. Perkins, G. W. Aherne, J. C. Reader, F. I. Raynaud, S. A. Eccles, I. Collins, M. D. Garrett, The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma, Oncotarget, 2016, 7, 2329–2342
- T. A. Yap, M. I. Walton, K. M. Grimshaw, R. H. te Poele, P. D. Eve, M. R. Valenti, A. K. de Haven Brandon, V. Martins, A. Zetterlund, S. P. Heaton, K. Heinzmann, P. S. Jones, R. E. Feltell, M. Reule, S. J. Woodhead, T. G. Davies, J. F. Lyons, F. I. Raynaud, S. A. Eccles, P. Workman, N. T. Thompson and M. D. Garrett, AT13148 Is a Novel, Oral Multi-AGC Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity, Clin. Cancer Res., 2012, 18, 3912–3923
Polyprodrugs:
- M. S. Akkad, C. J. Serpell, Degradable Polymers and Nanoparticles Built from Salicylic Acid, Macromol. Rapid Commun., 2018, 39, 1800182
- S. Shehata, C. J. Serpell, S. C. G. Biagini, Controlled Release of Ibuprofen from Polymeric Nanoparticles, Mater. Today Commun., 2020